CY1119895T1 - Εμβολια βιοπροϊοντος συζευξης καψικων gram-θετικων βακτηριδιων - Google Patents

Εμβολια βιοπροϊοντος συζευξης καψικων gram-θετικων βακτηριδιων

Info

Publication number
CY1119895T1
CY1119895T1 CY20181100148T CY181100148T CY1119895T1 CY 1119895 T1 CY1119895 T1 CY 1119895T1 CY 20181100148 T CY20181100148 T CY 20181100148T CY 181100148 T CY181100148 T CY 181100148T CY 1119895 T1 CY1119895 T1 CY 1119895T1
Authority
CY
Cyprus
Prior art keywords
positive
gram
directed
bioconjugate
vaccines
Prior art date
Application number
CY20181100148T
Other languages
English (en)
Inventor
Michael Wacker
Michael Kowarik
Michael Wetter
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of CY1119895T1 publication Critical patent/CY1119895T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Μία πραγματοποίηση της παρούσας εφεύρεσης κατευθύνεται σε ένα νέο εμβόλιο βιοπροϊόντος σύζευξης S. aureus. Γενικότερα, η εφεύρεση απευθύνεται σε Gram-θετικά και άλλου βιοπροϊόντος σύζευξης εμβόλια που περιλαμβάνουν: μία πρωτεΐνη φορέα που περιλαμβάνει εισαχθείσα αλληλουχία νουκλεϊνικού οξέος κοινής ομολογίας, τουλάχιστον ένα πολυσακχαρίδιο όπως καψικό Gram-θετικό πολυσακχαρίδιο που συνδέεται προς την συναινετική αλληλουχία και, προαιρετικώς, ανοσοενισχυτικό ή φαρμακευτικώς αποδεκτό φορέα. Σε μια περαιτέρω άποψη, η παρούσα εφεύρεση κατευθύνεται σε μεθόδους παραγωγής Gram-θετικών και άλλου βιοπροϊόντος σύζευξης εμβόλια. Σε άλλη άποψη, παρέχεται Ν-γλυκοζυλιωμένη πρωτεΐνη που περιλαμβάνει ένα ή περισσότερα πολυσακχαρίδιο όπως Gram-θετικά πολυσακχαρίδια. Η παρούσα εφεύρεση επιπροσθέτως κατευθύνεται σε γενετικά κατασκευασμένους προκαρυωτικούς οργανισμούς που περιλαμβάνουν αλληλουχίες νουκλεοτιδίου που κωδικοποιούν γλυκοζυλτρανσφεράση ενός πρώτου προκαρυωτικού οργανισμού και γλυκοζυλτρανσφεράση ενός δεύτερου προκαρυωτικού οργανισμού. Η εφεύρεση περαιτέρω περιλαμβάνει πλασμίδια και προκαρυωτικά κύτταρα μετασχηματισμένα με πλασμίδια που κωδικοποιούν πολυσακχαρίδια και ένζυμα τα οποία παράγουν N-γλυκοζυλιωμένη πρωτεΐνη ή/και εμβόλιο βιοπροϊόντος σύζευξης. Περαιτέρω, η εφεύρεση απευθύνεται σε μεθόδους διέγερσης ανοσοαπόκρισης σε ένα θηλαστικό που περιλαμβάνει χορήγηση των εν λόγω βιοπροϊόντος σύζευξης.
CY20181100148T 2010-05-06 2018-02-06 Εμβολια βιοπροϊοντος συζευξης καψικων gram-θετικων βακτηριδιων CY1119895T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33217010P 2010-05-06 2010-05-06
PCT/EP2011/057111 WO2011138361A1 (en) 2010-05-06 2011-05-04 Capsular gram-positive bacteria bioconjugate vaccines

Publications (1)

Publication Number Publication Date
CY1119895T1 true CY1119895T1 (el) 2018-06-27

Family

ID=44902091

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100148T CY1119895T1 (el) 2010-05-06 2018-02-06 Εμβολια βιοπροϊοντος συζευξης καψικων gram-θετικων βακτηριδιων

Country Status (20)

Country Link
US (3) US8871491B2 (el)
EP (2) EP3281639B1 (el)
JP (2) JP6339366B2 (el)
KR (2) KR101916290B1 (el)
CN (1) CN103079591B (el)
AU (2) AU2011249839B2 (el)
CA (1) CA2798381C (el)
CY (1) CY1119895T1 (el)
DK (1) DK2566507T3 (el)
ES (2) ES2657588T3 (el)
HR (1) HRP20180064T1 (el)
HU (1) HUE037956T2 (el)
IL (1) IL222711B (el)
LT (1) LT2566507T (el)
NO (1) NO2566507T3 (el)
PL (1) PL2566507T3 (el)
PT (1) PT2566507T (el)
SG (1) SG185433A1 (el)
SI (1) SI2566507T1 (el)
WO (1) WO2011138361A1 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481057B1 (en) * 2002-03-07 2006-02-15 Eidgenössische Technische Hochschule Zürich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
EP3427749A1 (en) 2008-02-20 2019-01-16 GlaxoSmithKline Biologicals SA Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
TR201803015T4 (tr) 2009-11-19 2018-03-21 Glaxosmithkline Biologicals Sa Prokaryotik hücrelerde immünojenik polisakaridler üreten biyosentetik sistem.
US9526775B2 (en) 2012-04-27 2016-12-27 Washington University Glycoengineered outer membrane vesicles and use thereof as vaccines
JP2015522692A (ja) 2012-07-16 2015-08-06 ファイザー・インク 糖およびその使用
BR112015001390B1 (pt) 2012-07-26 2024-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina
TR201904022T4 (tr) 2012-10-12 2019-04-22 Glaxosmithkline Biologicals Sa Konakçı hücre modifikasyon yöntemleri.
EP2917351B1 (en) 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
US9931392B2 (en) 2013-01-18 2018-04-03 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
SG11201602546RA (en) * 2013-10-11 2016-04-28 Glycovaxyn Ag Methods of host cell modification
JP2016540764A (ja) * 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
SI3131577T1 (sl) * 2014-04-17 2020-08-31 Glaxosmithkline Biologicals S.A. Modificirane gostiljske celice in uporabe le-teh
US10307474B2 (en) * 2014-08-08 2019-06-04 Glaxosmithkline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
AU2015342943B2 (en) * 2014-11-05 2018-06-28 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
PT3240895T (pt) 2014-12-30 2022-03-02 Glaxosmithkline Biologicals Sa Composições e métodos para glicosilação de proteínas
WO2017001586A1 (en) * 2015-07-01 2017-01-05 Glaxosmithkline Biologicals S.A. Immunogenic compositions
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
CN108330142B (zh) * 2018-02-09 2021-09-17 河北科技师范学院 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN109400704B (zh) * 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
JP2022517981A (ja) * 2019-01-11 2022-03-11 ノースウェスタン ユニバーシティ 原核細胞溶解物におけるバイオコンジュゲートワクチンの合成
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN112575041B (zh) * 2019-09-30 2022-12-13 江南大学 一种混合碳源高效发酵生产phb的工程菌及其应用
CA3185642A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
CN114085255B (zh) * 2020-08-24 2023-08-29 山东大学 一种苏黎世克罗诺杆菌5型脂多糖o-抗原寡糖片段及其制备方法与应用
WO2022171679A2 (en) 2021-02-11 2022-08-18 Glaxosmithkline Biologicals Sa Protein
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1900A (en) 1840-12-14 Machine for extracting stumps
ATE67786T1 (de) 1984-08-01 1991-10-15 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
WO1994026906A2 (en) 1993-05-14 1994-11-24 The Upjohn Company CLONED DNA ENCODING A UDP-GALNAc:POLYPEPTIDE,N-ACETYLGALACTOS AMINYLTRANSFERASE
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
CA2363297C (en) 1999-03-02 2011-08-09 Michael J. Betenbaugh Engineering intracellular sialylation pathways
US20020019342A1 (en) 2000-05-12 2002-02-14 Robert Bayer In vitro modification of glycosylation patterns of recombinant glycopeptides
CA2411968C (en) 2000-06-30 2009-12-15 Flanders Interuniversity Institute For Biotechnology (Vib) Protein glycosylation modification in pichia pastoris
EP1481057B1 (en) 2002-03-07 2006-02-15 Eidgenössische Technische Hochschule Zürich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
US20040265954A1 (en) 2002-03-07 2004-12-30 Markus Aebi System and method for the production of recombinant proteins
US7598354B2 (en) 2002-08-01 2009-10-06 National Research Council Of Canada Campylobacter glycans and glycopeptides
EP1756149B1 (en) 2004-05-24 2013-09-04 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Live, oral vaccine for protection against shigella dysenteriae serotype 1
EP1888761B1 (en) 2005-05-11 2010-09-29 ETH Zurich Recombinant n-glycosylated proteins from procaryotic cells
EP2476433A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20100286067A1 (en) * 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
EP3427749A1 (en) * 2008-02-20 2019-01-16 GlaxoSmithKline Biologicals SA Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells

Also Published As

Publication number Publication date
EP2566507A1 (en) 2013-03-13
JP6339366B2 (ja) 2018-06-06
PL2566507T3 (pl) 2018-05-30
ES2844596T3 (es) 2021-07-22
EP3281639B1 (en) 2020-11-11
JP2013524844A (ja) 2013-06-20
IL222711A0 (en) 2012-12-31
DK2566507T3 (da) 2018-01-29
NO2566507T3 (el) 2018-04-21
ES2657588T3 (es) 2018-03-06
US8871491B2 (en) 2014-10-28
HUE037956T2 (hu) 2018-09-28
CN103079591B (zh) 2017-07-28
US20170128559A1 (en) 2017-05-11
EP2566507B1 (en) 2017-11-22
KR20180021219A (ko) 2018-02-28
CA2798381A1 (en) 2011-11-10
LT2566507T (lt) 2018-02-12
HRP20180064T1 (hr) 2018-02-23
US9585950B2 (en) 2017-03-07
SI2566507T1 (en) 2018-04-30
US20150010592A1 (en) 2015-01-08
JP6435583B2 (ja) 2018-12-12
KR20130063510A (ko) 2013-06-14
US10307473B2 (en) 2019-06-04
KR101916290B1 (ko) 2018-11-09
PT2566507T (pt) 2018-02-06
CA2798381C (en) 2020-10-06
SG185433A1 (en) 2012-12-28
AU2011249839A1 (en) 2012-11-29
CN103079591A (zh) 2013-05-01
AU2016208265A1 (en) 2016-08-11
US20110274720A1 (en) 2011-11-10
WO2011138361A1 (en) 2011-11-10
IL222711B (en) 2018-10-31
AU2011249839B2 (en) 2016-05-26
EP3281639A1 (en) 2018-02-14
JP2017036303A (ja) 2017-02-16

Similar Documents

Publication Publication Date Title
CY1119895T1 (el) Εμβολια βιοπροϊοντος συζευξης καψικων gram-θετικων βακτηριδιων
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1125057T1 (el) Anti-cd277 αντισωματα και χρησεις αυτων
MX2022003994A (es) Produccion de oligosacaridos de leche humana en huespedes microbianos con importacion/exportacion dise?ada.
EA202090410A1 (ru) АГОНИСТЫ Toll-ПОДОБНОГО РЕЦЕПТОРА 7 (TLR7), ИМЕЮЩИЕ ПИРИДИНОВЫЙ ИЛИ ПИРАЗИНОВЫЙ ФРАГМЕНТ, ИХ КОНЪЮГАТЫ, ПРИМЕНЕНИЯ И СПОСОБЫ С НИМИ
MX336839B (es) Formacion de complejos de acidos nucleicos con componentes cationicos entrelazados por disulfuro para transfeccion e inmunoestimulacion.
MX2018014602A (es) Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
PH12020500101A1 (en) Novel muscosal adjuvants and delivery systems
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
BR112016007727A2 (pt) célula hospedeira, métodos para produzir um glicoconjugado, uma célula hospedeira e uma proteína n-glicosilada, para tratar ou prevenir uma infecção em um indivíduo e para induzir uma resposta imune em um indivíduo, glicoconjugado, kit, e, plasmídeo isolado
BR112012023692A2 (pt) imunoterapias contra vários tumores, incluindo câncer gastrointestinal e gástrico
EP4219536A3 (en) Targeted/immunomodulatory fusion proteins and methods for making same
BR112013020070A8 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
PH12015500308B1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
MX355501B (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
PH12016500360A1 (en) A bacterial vaccine and methods for manufacture thereof
WO2010045573A3 (en) Tumor vaccine
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
AU2014232363A8 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
GB2458057A (en) Francisella strain for live vaccine
MA32305B1 (fr) Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine